Scott Bizily
Vermögen: 87 721 $ am 31.07.2026
Vermögen: 87 721 $ am 31.07.2026
Dr. Scott P.
Bizily is a Secretary, Chief Compliance & Legal Officer at 4D Molecular Therapeutics, Inc. Dr. Bizily was previously employed as a General Counsel by Synthego Corp.
and a Director-Corporate Counsel by BioMarin Pharmaceutical, Inc. He received his graduate degree from the University of Pennsylvania and a doctorate degree from the University of Georgia.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 17.08.2026 | 8.617 ( 0,02 % ) | 87 721 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Compliance Officer | 01.12.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
Synthego Corp.
Synthego Corp. BiotechnologyHealth Technology Engages in research, development and manufactures CRISPR cell & gene therapies | General Counsel | 01.09.2021 |
| BIOMARIN PHARMACEUTICAL INC. | General Counsel | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Synthego Corp.
Synthego Corp. BiotechnologyHealth Technology Engages in research, development and manufactures CRISPR cell & gene therapies | Health Technology |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Georgia
University of Georgia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. BiotechnologyHealth Technology Designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen